6657.TW Energenesis Biomedical Co. Ltd.

Healthcare Biotechnology Taiwan Stock Exchange
29.60 TWD
Close of Nov 7, 2026
27.00 59.70
Market cap
TWD 2.60B
P/E
-
P/B
3.65x
ROE
-51.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6657.TW undervalued?

Graham number

The Graham number of Energenesis Biomedical Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Energenesis Biomedical Co. Ltd. fundamental analysis

No fundamental analysis for Energenesis Biomedical Co. Ltd. yet.

Energenesis Biomedical Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Energenesis Biomedical Co. Ltd.

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic …

Full company profile